|
| BML-275 Basic information |
Product Name: | BML-275 | Synonyms: | dorsoMorphin (Hydrochloride);DorsoMorphin, Dihydrochloride Salt, >99%;BML-275,Compound C;6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2) Dorsomorphin 2HCl;Dorsomorphin-2HCl
BML-275;6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)pyrazolo[1,5-a]pyrimidine hydrochloride (1:2);BML-275 dihydrochloride;Dorsomorphin(BML-275)dihydrochloride | CAS: | 1219168-18-9 | MF: | C24H27Cl2N5O | MW: | 472.41008 | EINECS: | | Product Categories: | PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K | Mol File: | 1219168-18-9.mol | |
| BML-275 Chemical Properties |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | solubility | insoluble in EtOH; insoluble in H2O; ≥11.34 mg/mL in 0.9% NS ; ≥39.93 mg/mL in DMSO:H2O=2:1 ; ≥5.91 mg/mL in DMSO | form | Light yellow powder solid. | color | Yellow | Stability: | Hygroscopic |
| BML-275 Usage And Synthesis |
Description | Dorsomorphin (hydrochloride) is a potent, reversible inhibitor of AMP kinase (AMPK; Ki = 109 nM) that does not exhibit significant activity on structurally related kinases, including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin can also dose-dependently inhibit the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6). Independent of AMPK inhibition, dorsomorphin, at 10 μM, has additionally been shown to downregulate the Akt/mTOR pathway to induce autophagy in U251 human glioma cells. | Uses | Dorsomorphin is an AMP-activated kinase (AMPK) inhibitor. Dorsomorphin selectively inhibits the bone morphogenetic protein (BMP) type I receptors ALK2, ALK3 and ALK6 and thus blocks BMP-mediated SMAD1/5/8 phosphorylation, target gene transcription and osteogenic differentiation. Dorsomorphin has shown to increase cisplatin-induced apoptosis, which was associated with hyper-induction of the tumor suppressor p53. | storage | Room temperature (desiccate) |
| BML-275 Preparation Products And Raw materials |
|